Search details
1.
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.
Cell
; 173(3): 624-633.e8, 2018 04 19.
Article
in English
| MEDLINE | ID: mdl-29656892
2.
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet
; 403(10427): 632-644, 2024 Feb 17.
Article
in English
| MEDLINE | ID: mdl-38246194
3.
CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy.
J Immunol
; 211(5): 735-742, 2023 09 01.
Article
in English
| MEDLINE | ID: mdl-37466381
4.
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Cancer Immunol Immunother
; 72(4): 945-954, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36197494
5.
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
J Transl Med
; 21(1): 508, 2023 07 28.
Article
in English
| MEDLINE | ID: mdl-37507765
6.
Risk and tropism of central nervous system (CNS) metastases in patients with stage II and III cutaneous melanoma.
Cancer
; 128(20): 3620-3629, 2022 10.
Article
in English
| MEDLINE | ID: mdl-36006879
7.
Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?
J Neurooncol
; 158(3): 471-480, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35665462
8.
American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach.
Endocr Pract
; 28(7): 719-731, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35477029
9.
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020.
J Transl Med
; 19(1): 142, 2021 04 07.
Article
in English
| MEDLINE | ID: mdl-33827575
10.
Management of Melanoma during Pregnancy: A Case Series of 11 Women Treated at NYU Langone Health.
Oncology
; 98(12): 847-852, 2020.
Article
in English
| MEDLINE | ID: mdl-32894847
11.
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
N Engl J Med
; 375(19): 1845-1855, 2016 11 10.
Article
in English
| MEDLINE | ID: mdl-27717298
12.
Osteochondral Defect of the Calcaneocuboid Joint: A Case Study.
J Foot Ankle Surg
; 58(3): 567-572, 2019 May.
Article
in English
| MEDLINE | ID: mdl-30803911
13.
Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
Cancer
; 124(2): 297-305, 2018 01 15.
Article
in English
| MEDLINE | ID: mdl-29023643
14.
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Cancer Immunol Immunother
; 72(4): 955, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36538061
15.
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
Cancer Immunol Immunother
; 67(3): 381-392, 2018 03.
Article
in English
| MEDLINE | ID: mdl-29124315
16.
Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.
J Neurooncol
; 138(1): 183-190, 2018 May.
Article
in English
| MEDLINE | ID: mdl-29427150
17.
Are vaccines making a comeback in melanoma?
Clin Adv Hematol Oncol
; 21(11): 603-605, 2023 11.
Article
in English
| MEDLINE | ID: mdl-37948598
18.
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 18(3): 393-403, 2017 03.
Article
in English
| MEDLINE | ID: mdl-28162999
19.
PD-1 and PD-L1 antibodies in cancer: current status and future directions.
Cancer Immunol Immunother
; 66(5): 551-564, 2017 May.
Article
in English
| MEDLINE | ID: mdl-28213726
20.
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Lancet Oncol
; 17(7): 943-955, 2016 Jul.
Article
in English
| MEDLINE | ID: mdl-27269740